Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Net Income (2020 - 2025)

Insight Molecular Diagnostics' Net Income history spans 6 years, with the latest figure at -$11.0 million for Q3 2025.

  • For Q3 2025, Net Income rose 18.25% year-over-year to -$11.0 million; the TTM value through Sep 2025 reached -$61.3 million, down 124.8%, while the annual FY2024 figure was -$61.0 million, 1986.16% down from the prior year.
  • Net Income for Q3 2025 was -$11.0 million at Insight Molecular Diagnostics, down from -$9.8 million in the prior quarter.
  • Across five years, Net Income topped out at -$2.9 million in Q1 2023 and bottomed at -$35.7 million in Q4 2021.
  • The 5-year median for Net Income is -$9.5 million (2024), against an average of -$13.3 million.
  • The largest YoY upside for Net Income was 60.5% in 2021 against a maximum downside of 438.57% in 2021.
  • A 5-year view of Net Income shows it stood at -$35.7 million in 2021, then rose by 7.65% to -$33.0 million in 2022, then soared by 91.12% to -$2.9 million in 2023, then plummeted by 1049.25% to -$33.6 million in 2024, then surged by 67.15% to -$11.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Net Income are -$11.0 million (Q3 2025), -$9.8 million (Q2 2025), and -$6.8 million (Q1 2025).